Stay updated with breaking news from Compass Pathway. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
By Sriparna Roy and Pratik Jain (Reuters) - A panel of advisers to the U.S. Food and Drug Administration will meet on Tuesday to discuss a therapy based on the psychedelic drug MDMA for patients with post-traumatic stress disorder (PTSD). The meet...
New research led by the University of Bristol has explored the neuropsychological effects of rapid-acting antidepressants, including ketamine, scopolamine and p
"Mad Money" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed.
By Sabela Ojea International stocks trading in New York closed lower on Tuesday. The S&P/BNY Mellon index of American depositary receipts fell 1.5% to 148.45. The European index dived 1.6% to 145.63, the Asian index declined 1.3% to 168.53... | May. 30
Compass Pathways is running a massive clinical trial that will likely help it turn a psychedelic substance into an approved medicine.